Ironwood Q2 FY26 GAAP net income rises 117% to $51.29 million; revenue increases 33% to $113.04 million

Reuters2026/08/06 11:19

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Ironwood Pharmaceuticals posted Q2 2026 GAAP net income of $51.29 million, with total revenue up 32.62% to $113.04 million.
Adjusted EBITDA rose 65.75% to $83.04 million, while total costs and expenses fell 15.49% to $33.73 million.
LINZESS U.S. net sales increased 14% to $282.3 million; collaboration revenue climbed 28% to $110 million.
Cash and cash equivalents ended Q2 at $79.13 million; Ironwood repaid $200 million of 1.50% convertible senior notes at maturity in June.
Raised 2026 guidance for LINZESS U.S. net sales to $1.15-$1.2 billion, total revenue to $460-$485 million, adjusted EBITDA to more than $310 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ironwood Pharmaceuticals Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Ironwood Q2 FY26 GAAP net income rises 117% to $51.29 million; revenue increases 33% to $113.04 million

You may also like

Crypto prices